279 reports of this reaction
3.5% of all NORGESTIMATE AND ETHINYL ESTRADIOL reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for NORGESTIMATE AND ETHINYL ESTRADIOL, manufactured by Teva Pharmaceuticals USA, Inc.. There are 279 FDA adverse event reports linking NORGESTIMATE AND ETHINYL ESTRADIOL to HEADACHE. This represents approximately 3.5% of all 7,959 adverse event reports for this drug.
Patients taking NORGESTIMATE AND ETHINYL ESTRADIOL who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among NORGESTIMATE AND ETHINYL ESTRADIOL users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for NORGESTIMATE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 279 FDA reports for NORGESTIMATE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.5% of all adverse event reports for NORGESTIMATE AND ETHINYL ESTRADIOL, making it one of the most commonly reported side effect.
If you experience headache while taking NORGESTIMATE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.